Barely Significant
← all excerpts

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations.

BMC Cancer · 2021 · PMC8091516 · PMID 33941115

Europe PMCDOI
1
hedged sentence
0.0640
closest p · 1.3× alpha
0.0640
boldest claim

The sentences

showed a trendp = 0.0640so close (0.05 < p ≤ 0.1)
In the model 2 of multivariable analysis, considering the detailed metastatic sites instead of number of metastatic sites, we found exon 21 (HR [95% CI]: 1.56 [1.04–2.36], p = 0.0336), pleural metastasis/effusion (HR [95% CI]: 1.77 [1.17–2.69], p = 0.0075), and bone metastasis (HR [95% CI]: 1.69 [1.13–2.55], p = 0.0116) were independent risk factors for poorer PFS, while dose reduction showed a trend toward better PFS (HR [95% CI]: 0.59 [0.34–1.03], p = 0.0640).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.